Yield10 Bioscience (NASDAQ:YTEN) is an agricultural bioscience company focused on developing breakthrough technologies to improve crop yield and oilseed composition. Headquartered in Woburn, Massachusetts, Yield10 leverages advanced gene editing, genome engineering, and metabolic engineering platforms to identify and optimize key genetic traits in food and feed crops. By targeting pathways such as photosynthesis efficiency and carbon use, the company aims to address global food security challenges and support sustainable agriculture.
Originally established as a subsidiary of Metabolix, Inc., Yield10 Bioscience was spun off in 2015 to concentrate exclusively on agricultural applications. Since then, the company has built a robust pipeline of trait development programs, including projects aimed at increasing seed oil content in Camelina sativa and pennycress, as well as enhancing yield potential in canola and soybean. Yield10’s pipeline features proprietary technologies such as the “Trait Factory” platform, which accelerates identification of genes that boost biomass and seed yield under field conditions.
Yield10 conducts research and field trials across North America in collaboration with public research institutions and strategic industry partners. Its multi‐phase approach includes greenhouse validation, confined field testing, and regulatory pathways to support commercial adoption. The company also explores development of specialty fatty acids and high-value crop traits that align with evolving market demands for plant-derived oils and agricultural commodities.
Under the leadership of CEO Oliver Peoples, Yield10 Bioscience is governed by a team of experienced scientists and business executives with deep expertise in biotechnology, agronomy, and commercial development. The company continues to pursue partnerships and licensing opportunities to accelerate the integration of its yield-improving traits into major row crops, positioning it at the forefront of next-generation crop innovation.
